All In Biotech

Drug Trial Radar · NCT06635824

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 191 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

191

Actual

Start

Nov 25, 2024

Primary completion

Jul 30, 2027

Study completion Sep 30, 2028

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
Oct 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluate the efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel (standard of care) in participants with locally advanced (unresectable stage IIIB/C) or programmed death ligand 1 (PD-L1)-positive metastatic non-small cell lung cancer (NSCLC) who have been treated with programmed cell death protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administered either in combination or sequentially in the locally advanced (unresectable stage IIIB/C) or metastatic setting.

Conditions

  • PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC

Interventions

  • AcasunlimabDrug

    IV infusion

  • PembrolizumabDrug

    IV infusion

  • DocetaxelDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to approximately 5 years

Locations

247 sites in 27 countries. Site status is shown where the registry gives one.

  • Arizona Blood and Cancer Specialists

    Tucson, Arizona

  • Usc Norris Comprehensive Cancer Center

    Los Angeles, California

  • Kaiser Permanente Vallejo Medical Center

    Vallejo, California

  • Ocala Oncology Center P.L.

    Ocala, Florida

  • Orlando Regional Medical Center

    Orlando, Florida

  • University Cancer & Blood Center, LLC

    Athens, Georgia

  • Piedmont Cancer Institute Atlanta

    Atlanta, Georgia

  • Piedmont Cancer Institute - Sandy Springs (Atlanta) Office

    Atlanta, Georgia

  • Piedmont Cancer Institute - Fayetteville Office

    Fayetteville, Georgia

  • Piedmont Cancer Institute - Newnan Office

    Newnan, Georgia

  • Piedmont Cancer Institute - Stockbridge Office

    Stockbridge, Georgia

  • Kaiser Foundation Hospitals

    Honolulu, Hawaii

  • University of Illinois

    Chicago, Illinois

  • Community Cancer Center East Medical Oncology Hematology

    Indianapolis, Indiana

  • Baptist Health Lexington

    Lexington, Kentucky

  • Norton Cancer Institute

    Louisville, Kentucky

  • Pikeville Medical Center

    Pikeville, Kentucky

  • Washington University School of Medicine

    St Louis, Missouri

  • St. Francis Hospital - Grand Island

    Grand Island, Nebraska

  • Oncology Hematology West

    Omaha, Nebraska

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists

    Omaha, Nebraska

  • Stony Brook University Medical Center|University Medical Center

    Stony Brook, New York

  • Novant Health Pharmacy

    Charlotte, North Carolina

  • Novant Health Oncology Specialists

    Winston-Salem, North Carolina

  • University of Pennsylvania Health System

    Philadelphia, Pennsylvania

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • Avera Cancer Institute

    Sioux Falls, South Dakota

  • Parkridge Medical Center

    Chattanooga, Tennessee

  • University of Tennessee Medical Center Cancer Institute

    Knoxville, Tennessee

  • Midtown Tennessee Oncology

    Nashville, Tennessee

  • Tennessee Oncology

    Nashville, Tennessee

  • Texas Oncology-Austin Midtown

    Austin, Texas

  • Texas Oncology-Austin Central

    Austin, Texas

  • South Austin Cancer Ctr

    Austin, Texas

  • University of Virginia Hematology and Oncology

    Charlottesville, Virginia

  • Cancer Institute At Swedish Med Ctr

    Seattle, Washington

  • Hospital Italiano de Buenos Aires

    Ciudad Autonoma Buenos Aires, Argentina

  • Investigaciones CORI S.R.L.

    La Rioja, Argentina

  • Hospital Italiano de La Plata

    La Plata, Buenos Aires, Argentina

  • Centro de Investigacion Pergamino S.A.

    Pergamino, Buenos Aires, Argentina

Showing 40 of 247 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.